ComBio: Flii and the elephant in the room
18 September, 2008 by Fiona WylieA symposium at ComBio on wound healing promises to take audiences on a journey from basic cell biology right through to 3D skin scaffolds as therapies.
Funds for venture capitalists
18 September, 2008 by Kate McDonaldThree new fund managers selected for Innovation Investment Fund
NuSep licences gels
17 September, 2008 by Dylan Bushell-EmblingNuSep to licence out electrophoresis gels business
ChemGenex raises $12.9m
17 September, 2008 by Dylan Bushell-EmblingMajor shareholders chip in half of capital raising
HeartWare vote for US move
17 September, 2008 by Dylan Bushell-EmblingCourt approves shareholder vote on HeartWare's plans to redomicile
CathRx sells first product to Europe
17 September, 2008 by Dylan Bushell-EmblingDiagnostic modular heart catheters first of several planned for European market
Vascular patent for HealthLinx
17 September, 2008 by Dylan Bushell-EmblingHealthLinx granted US patent for vascular permeability program
Leggett action continues
16 September, 2008 by Dylan Bushell-EmblingLitigation against former Agenix CEO Neil Leggett to continue next week
Pharmaxis banks
16 September, 2008 by Dylan Bushell-EmblingPharmaxis in strong cash position for FY09
BioDiem at Portugal flu conference
16 September, 2008 by Dylan Bushell-EmblingBioDiem presents LAIV research at influenza conference
Millipore product guide to antibodies
16 September, 2008 by External Press Release AuthorMillipore announces the availability of its new Antibodies and Kits Product Guide, a comprehensive resource for navigating Millipore’s antibodies, immunoassay products and recombinant proteins for over 2500 unique targets.
Vaccines and the world
12 September, 2008 by Staff WritersThe World Vaccines Congress is coming to Sydney next month
BioLayer assays Prince of Wales
10 September, 2008 by Dylan Bushell-EmblingBioLayer to partner with Prince of Wales to develop Parkinson's detection tools
Venturous Australia: innovation review released
09 September, 2008 by Kate McDonaldR&D tax credits, pre-seed grants, full funding of university research recommended
Peplin into Phase III
09 September, 2008 by Dylan Bushell-EmblingPeplin to conduct Phase III trial of PEP005 under special protocol assessment
